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HLA-identical allogeneic hematopoietic stem cell transplanta-
tion (SCT) is a curative therapy for various forms of hematologi-
cal malignancies (1). It has become the treatment of choice for 
patients with chronic myeloid leukemia (CML) and is currently 
the most effective consolidation treatment for patients with acute 
leukemia (2, 3). The therapeutic efficacy is attributed to the graft-
versus-leukemia (GVL) reaction, an immune response in which 
donor-derived CTLs eliminate malignant cells of the recipient (4, 
5). Minor histocompatibility antigens (mHAgs) are the target anti-
gens of the GVL response, and expansion of mHAg-specific CTLs 
has been shown to precede clinical remission in relapsed CML 
patients treated with donor lymphocyte infusions (DLIs) (6, 7). 
However, alloreactive CTL responses induced upon DLI generally 
lack tumor specificity and are often accompanied by graft-versus-
host disease (GVHD). Selective GVL responses in the absence of 
GVHD may result from mHAgs with expression limited to hema-
topoietic cells such as HA-1 (8), HA-2 (9, 10), and BCL2A1 (11) or 
to lineage-specific hematopoietic cells such as HB-1 (12, 13). These 
hematopoietic cell–restricted antigens represent potential targets 
for specific immunotherapy after allogeneic SCT (14–16).
mHAgs are HLA-bound peptides derived from cellular proteins 
that differ in amino acid sequence between donor and recipient 
due to genetic polymorphisms (4, 17–19). Thus far, approximately 
15 human mHAgs have been identified through mass spectrom-
etry of HLA-eluted peptides (8, 9, 20–24), cDNA library cloning 
(13, 25), or genetic linkage analysis (11). Immunogenicity of most 
of the molecularly characterized human mHAgs results from 
single nucleotide polymorphisms (SNPs) in homologous donor 
and recipient genes causing amino acid substitutions within the 
epitope (8–11, 13, 20–24). In 1 instance, an mHAg encoded by the 
UGT2B17 gene resulted from differential protein expression in 
donor and recipient cells as a consequence of a homozygous gene 
deletion in the donor (25).
Here, we report the identification of a novel hematopoietic cell–
restricted mHAg, designated lymphoid-restricted histocompat-
ibility antigen–1 (LRH-1), which elicited an HLA-B7–restricted 
CTL response in a CML patient treated with DLI. Using genetic 
linkage analysis and gene profiling, we have identified P2X5 as 
the polymorphic gene encoding the LRH-1 antigenic peptide. 
Our data provide what we believe to be the first evidence that 
mHAg disparity can result from differential protein expression 
due to a homozygous frameshift polymorphism. Furthermore, 
we have analyzed the kinetics of the LRH-1–specific CTL response 
in the CML patient and show that emergence of LRH-1/B7 
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tetramer+ T cells is associated with GVL reactivity following 
DLI. Finally, our observation that LRH-1 is selectively expressed 
within the hematopoietic system including leukemic CD34+ pro-
genitor cells offers a novel target antigen for the development of 
immunotherapy for the treatment of relapsed leukemia.
Results
Case description. In 1996, we transplanted a marrow graft into a 
35-year-old woman (UPN389) with Philadelphia chromosome–
positive (Ph+) CML from her HLA-identical brother (A24, A29, B7, 
B44, Cw7, Cw16) after receiving informed consent. Partial T cell 
depletion was performed using counterflow centrifugation, and 
0.8 × 106 CD3+ cells/kg body weight were given within the graft 
(26). The patient suffered from acute GVHD grade III (skin and 
liver), which was successfully treated with the addition of corti-
costeroids. At 6 months after SCT, FISH analysis of a BM aspirate 
showed 7.5% Ph+ cells. Cyclosporin A (CsA) and corticosteroids 
were gradually withdrawn within 2 months without reactivation 
of GVHD. However, 1 month after cessation of immunosuppres-
sive treatment, Ph+ cells increased to 85% in the BM. Furthermore, 
these cells had additional chromosomal abnormalities with del(13) 
and t(4;11), and the patient had progressed to accelerated phase. 
The patient was given lymphocytes from the original BM donor 
(DLI-1; 0.1 × 108 CD3+ cells/kg body weight) but did not respond. 
After a second and higher dose of DLI (DLI-2; 0.7 × 108 CD3+ 
cells/kg body weight), the patient developed GVHD of the skin 
and pancytopenia. For GVHD of the skin, she was treated with 
CsA and mycophenolate mofetil for different intervals. Six months 
after DLI-2, BM cells were of donor origin. Since the patient had 
become and remained pancytopenic, she was given a T cell–deplet-
ed marrow booster from her donor. Nine months after DLI-2 and 
2 months after the stem cell booster, the patient was in complete 
cytogenetic and molecular remission.
CTL RP1 recognizes an HLA-B7–restricted mHAg expressed on hematopoi-
etic cells. To isolate mHAg-specific CD8+ T cells involved in the GVL 
response in CML patient UPN389, we stimulated PBMCs obtained 
3 months after DLI-2 with CML cells obtained at hematological 
relapse.	After multiple stimulations, TCR repertoire analysis revealed 
that more than 90% of CD8+ T cells expressed a clonal TCR-BV21.3 
chain (data not shown). This CD8+ CTL clone, termed RP1, mediated 
specific lysis against the EBV–lymphoblastoid cell line (EBV-LCL) of 
the recipient, but not against donor EBV-LCL and NK-sensitive K562 
cells (Figure 1A). Specific lysis of recipient EBV-LCL was substantially 
inhibited by anti–HLA class I and anti–HLA-B/C Abs, but not by Ab 
against anti–HLA class II, indicating recognition of an HLA class I–
restricted mHAg (data not shown). Testing of EBV-LCLs from unre-
lated individuals sharing expression of HLA-B7 with the recipient 
and EBV-LCL from an HLA class I–mismatched individual that were 
transduced with HLA-B*0702 revealed that CTL RP1 recognizes an 
mHAg presented by HLA-B7 (Figure 1B).
Figure 1
Specific reactivity of HLA-B*0702–restricted CTL RP1 against hematopoietic cells. (A) Specific cytotoxicity was tested in 51Cr release assays 
against EBV-LCLs of the recipient (Rt) and donor (Do). NK-sensitive K562 cells were used to determine nonspecific lysis. Effector to target (E/T) 
ratios are indicated. (B) Production of IFN-γ by CTL RP1 stimulated with recipient EBV-LCLs, EBV-LCLs of 2 unrelated individuals (nos. 1 and 2) 
sharing HLA-B7 with the recipient, and an EBV-LCL of an HLA class I–mismatched individual (no. 3) that was transduced with HLA-B*0702. Data 
are displayed as mean IFN-γ release ± SD of triplicate wells. (C) Specific cytotoxicity against hematopoietic cells of lymphoid origin (EBV-LCLs, 
PHA-stimulated T cells, and CD40L-stimulated B cells) and BM-derived fibroblasts incubated with 10 ng/ml TNF-α and 100 U/ml IFN-γ for 
2 days before 51Cr labeling. The E/T ratio was 1:1. (D) IFN-γ production by CTL RP1 upon stimulation with hematopoietic cells of myeloid origin 
(monocytes, immature DCs [iDC] and mature DCs [mDC]).
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Next we investigated whether the mHAg recognized by CTL RP1 
was selectively expressed by hematopoietic cells. CTL RP1 signifi-
cantly lysed cells of lymphoid origin such as EBV-LCLs, CD40-
activated B cells, and phytohemagglutinin-stimulated (PHA-
stimulated) T cells, whereas monocytes and monocyte-derived 
DCs were not recognized (Figure 1, C and D). Furthermore, no 
cytotoxicity of CTL RP1 was observed against TNF-α– and IFN-γ– 
pretreated BM-derived fibroblasts (Figure 1C). By contrast, all tar-
get cell types were significantly recognized by the allo–HLA-B7– 
specific CTL KOR18, indicating their susceptibility to CTL-medi-
ated recognition (data not shown). Together these data indicate 
that CTL RP1 recognizes an HLA-B7–restricted mHAg that is 
expressed by hematopoietic cells of the lymphoid lineage. Based 
on this CTL recognition pattern, we provisionally designated this 
novel mHAg as LRH-1.
The gene encoding LRH-1 is mapped to a 1.64-Mb region on chromosome 
17p13.2. We performed genetic linkage analysis to map the chro-
mosomal region containing the LRH-1–encoding gene. EBV-LCLs	
Figure 2
The LRH-1 locus is closely linked to a cluster of markers on chromosome 17p13.2. (A) LRH-1 segregation pattern for individuals of the CEPH 
pedigrees 1331, 1332, 1347, 1413, 1362, and 102. EBV-LCLs of all available family members were transduced with HLA-B*0702 and tested for 
recognition by CTL RP1. Filled circles (females) or squares (males) represent individuals scored as positive for the LRH-1 phenotype, and open 
circles (females) or squares (males) represent individuals scored as negative. Shaded symbols represent individuals from whom no EBV-LCLs 
was available. (B) Genetic map of chromosome 17p13.2 showing relative marker loci oriented with the centromere at the bottom of the figure. 
lod scores summed for all available families used in the linkage analysis are shown to the right of each genomic marker. CEPH families that are 
not genotyped for a particular marker and therefore not included in the linkage analysis are indicated in parentheses.
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from parental individuals of 13 Centre d’Etude du Polymorphism 
Humain (CEPH) families (provided by P. Martin, Fred Hutchinson 
Cancer Research Center, Seattle, Washington, USA) were trans-
duced with HLA-B*0702 and tested for CTL RP1 recognition. Six 
CEPH families (i.e., 1331, 1332, 1347, 1362, 1413, and 102), of 
which either one or both parents were positive, were selected for 
further study. CTL RP1 recognition of HLA-B*0702–transduced 
EBV-LCLs from all individuals of these families yielded informa-
tive LRH-1 segregation patterns for genome-wide linkage analysis 
(Figure 2A). All HLA-B*0702–transduced EBV-LCLs were signifi-
cantly recognized by the allo–HLA-B7–specific CTL KOR18, indi-
cating that the HLA-restriction molecule was properly expressed 
(data not shown). A cluster of markers on chromosome 17p13.2 
was significantly linked (i.e., log odds ratio [lod] scores > 3.0) to 
the locus encoding LRH-1 (Figure 2B). The maximum lod score 
obtained was 13.77 at θ = 0.001 for marker D17S1810. A 7.5-cM 
critical region of no recombination was defined between the 
flanking markers D17S1845 (7.19 cM) and D17S938 (14.69 cM) 
on the Marshfield genetic map. This region corresponds to a dis-
tance of 3.5 Mb according to the UCSC Genome Bioinformatics 
database (http://genome.ucsc.edu/; ref. 27).
To narrow down the genetic region that includes the LRH-1 
locus, we performed haplotype analysis using markers between 
D17S831 and D17S796. This analysis identified informative 
recombinant haplotypes in individual 13182 of family 102, indi-
vidual 4889 of family 1332, and individual 8564 of family 1362 
(Table 1). The recombinant paternal haplotype inherited by 
individual 13182 in family 102 indicated that the gene encoding 
LRH-1 is located telomeric to marker D17S1876. In an analogous 
fashion, the recombinant maternal haplotype inherited by indi-
vidual 4889 in family 1332 and the recombinant paternal haplo-
type inherited by individual 8564 in family 1362 implied that the 
LRH-1–coding gene lies centromeric to marker D17S1845. Taken 
together, these data indicated that the gene encoding LRH-1 is 
located between marker D17S1845 and D17S1876, a region of 
1.64 Mb on chromosome 17p13.2.
Identification of P2X5 as the gene encoding LRH-1. In the region 
deduced from linkage analysis, we identified 30 known genes using 
the NCBI (http://www.ncbi.nlm.nih.gov/) and UCSC Genome Bio-
informatics databases. Eleven of these genes represented members 
of the olfactory receptor gene family and were excluded from fur-
ther analysis. For the remaining 19 candidate genes, we developed 
real-time quantitative PCR and determined the expression level of 
each candidate gene in LRH-1–positive (EBV-LCL and Raji) and 
LRH-1–negative cell types (monocytes and fibroblasts). Expression 
profiles of CTNS, P2X5, and ATP2A3 were most closely associated 
with the pattern of recognition by CTL RP1 (Table 2). However, the 
expression level of CTNS and ATP2A3 was only 2- to 3-fold lower 
in monocytes compared with EBV-LCL, whereas P2X5 mRNA was 
expressed at a 20-fold-lower level. Furthermore, P2X5 mRNA was 
not detected in fibroblasts. These data suggested that the P2X5 
gene was the most likely candidate gene to encode LRH-1.
To confirm these results, we constructed expression plasmids 
encoding the P2X5 isoforms 1 and 2 using cDNA isolated from the 
homozygous LRH-1–positive CEPH individual 1331-8234. P2X5 
isoform 2 lacks exon 3 (i.e., 24 aas) and 1 codon in exon 7. CTL RP1 
efficiently recognized 293T-HLA-B*0702	cells transfected with 
P2X5 isoform 1, whereas isoform 2 was not recognized (Figure 3A). 
Both P2X5 isoforms cloned from the homozygous LRH-1–nega-
tive donor EBV-LCLs did not stimulate IFN-γ release by CTL RP1 
(Figure 3A). Furthermore, 293T-HLA-B*0702 cells transfected 
with a deletion construct encoding exons 1–5 of P2X5 isoform 1 
Table 1
Haplotypes of the parental probands and their informative offspring who had a recombination between the markers D17S831 and D17S796A
	 	Family	102	 Family	1332	 Family	1362
Genomic	 Position		 Father	 Mother	 Child	 Father	 Mother	 Child	 Father	 Mother	 Child	
markerB	 (bp)	 (13180)	 (13181)	 (13182)	 (8260)	 (8262)	 (4889)	 (8563)	 (8574)	 (8564)
D17S831 2116991 6 2 7 1 6 7 6 2 8 1 6 1 3 1 6 2 3 2
D17S1528 2231368 1 2 2 3 1 2 5 2 2 8 5 8 3 3 2 2 3 2
D17S1845 2911459 4 2 6 1 4 6 8 5 9 10 8 10 5 3 4 3 5 3
D17S126 3268519 1 1 1 2 1 1 1 1 1 1 1 1 2 1 2 1 1 1
D17S1152 3509013 0 0 0 0 0 0 4 2 4 4 4 4 1 5 5 3 5 3
D17S829 3751859 3 4 4 4 3 4 2 2 3 3 2 3 5 4 3 6 4 6
D17S1298 3873140 1 1 3 1 1 3 1 3 1 3 1 1 2 3 2 2 3 2
D17S1828 4016949 3 4 3 4 3 3 4 3 1 1 4 1 1 1 4 6 1 6
D17S1876 4551611 4 3 3 3 3 3 1 2 5 4 1 5 8 3 8 6 3 6
D17S1810 5229472 6 2 1 1 2 1 1 2 3 1 1 3 4 1 1 1 1 1
D17S1832 6173140 6 7 4 4 7 4 4 4 8 1 4 8 3 3 5 3 3 3
D17S938 6449833 1 2 3 3 2 3 3 5 3 2 3 3 2 7 5 2 7 2
D17S796 6452087 7 1 5 5 1 5 2 3 1 4 2 1 1 6 3 4 6 4
CTL recognitionC  +  +  +  –  +  +  +  –  – 
AThe genotypes are arranged by haplotype, with the paternally and maternally inherited haplotypes on the left and right, respectively. The haplotypes carry-
ing the LRH-1–positive phenotype are shown in red and blue. Their LRH-1–negative counterparts are indicated in green. 0 indicates that the genotype was 
not available in the CEPH database. Recombinant haplotypes of individuals 102-13182, 1332-4889, and 1362-8564 are represented by 2 different colors. 
Recombination events in these individuals point out that the region within which the LRH-1 locus resides is defined by the flanking markers D17S1845 and 
D17S1876, indicated by line spaces. BGenetic markers available in the CEPH database are positioned according to the physical chromosomal map in the 
UCSC Genome Bioinformatics database (July 2003 freeze). CRecognition of EBV-LCLs of each individual by CTL RP1.
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from CEPH individual 1331-8234 were efficiently recognized by 
CTL RP1 (Figure 3A). Collectively, these data demonstrate that 
the LRH-1 antigenic epitope is derived from the 24-aa sequence 
encoded by exon 3 of P2X5 isoform 1.
A single nucleotide deletion polymorphism in the P2X5 gene determines 
CTL recognition. We searched the human genome database for pre-
viously identified polymorphisms in exon 3 of P2X5 and found a 
cytosine deletion polymorphism in the region encoding aas 110 
and 111 of P2X5 isoform 1 (Figure 3B). To determine whether 
this polymorphism could be involved in recognition by CTL RP1, 
we sequenced and compared the P2X5 exon 3 sequence (72 bp in 
length) from the homozygous LRH-1–negative donor EBV-LCL 
and the homozygous LRH-1–positive EBV-LCL of CEPH individ-
ual 1331–8234. Interestingly, 1 cytosine nucleotide in the donor 
P2X5 exon 3 sequence was indeed deleted between bp 329 and 
333 of the open reading frame, resulting in a frameshift at aa 
position 112 and a putative truncated P2X5 protein of 146 aas 
(Figure 3B). These results demonstrate that a single nucleotide 
deletion polymorphism in the P2X5 sequence controls expres-
sion of the LRH-1 antigenic epitope.
Identification of the HLA-B7–restricted LRH-1 antigenic epitope. As a 
result of the deletion polymorphism in exon 3, the P2X5 isoform 1 
of the recipient contains a disparate NQRQNVCAE sequence com-
pared with that of the donor (Figure 3B). To identify the antigenic 
epitope, we analyzed this disparate sequence flanked at both sides 
by 9	naturally occurring aas for HLA-B7–binding peptides using 
BIMAS prediction software. This resulted in the identification 
of the nonamer peptide TPNQRQNVC and the decamer peptide 
TPNQRQNVCA, which both have a predicted BIMAS binding 
score of 2.0. We synthesized these peptides and tested their abil-
ity to stimulate IFN-γ release by CTL RP1 upon loading on donor 
EBV-LCL at various concentrations. Both peptides were efficiently 
recognized by CTL RP1 (Figure 3C). However, half-maximal IFN-γ 
release for the 9-mer peptide was obtained at pulsing EBV-LCL 
with approximately 150 nM, whereas the 10-mer peptide showed 
half-maximal IFN-γ release at a concentration of approximately 
350 nM, suggesting higher avidity of CTL RP1 for the 9-mer epit-
ope. Furthermore, HLA-B7 tetramers constructed with the 9-mer 
peptide efficiently stained CTL RP1, whereas HLA-B7 tetramers 
constructed with the 10-mer peptide were negative (data not 
shown). To further define the minimal epitope, we tested truncated 
versions of the 9-mer peptide. A peptide with a deletion of the Thr 
aa residue at the NH2 terminus failed to sensitize donor EBV-LCLs 
even at very high peptide concentrations, indicating that the Thr 
is the N-terminal end of the naturally processed peptide. Deletion 
of the Cys aa residue at the COOH terminus also resulted in a sig-
nificant decrease in recognition (Figure 3C). Taken together, these 
data indicated that the 9-mer TPNQRQNVC peptide is the natu-
rally presented epitope at the cell surface by HLA-B7 molecules 
that is recognized by CTL RP1.
Expansion of LRH-1–specific CD8+ T cells after DLI precedes remission of 
leukemia. To detect LRH-1–specific CD8+ T cells in vivo, we construct-
ed an HLA-B7 tetramer using the 9-mer peptide TPNQRQNVC. 
Before DLI, tetramer+ cells could not be detected (≤0.01%) in the 
peripheral blood of CML patient UPN389 (data not shown), where-
as LRH-1–specific CD8+ T cells were clearly detectable after DLI-2 
(Figure 4). The PBMC sample that was used for isolation of CTL 
RP1 contained 0.27% of tetramer+ cells among CD8+ T cells. This 
percentage increased rapidly in the peripheral blood to a peak level 
of 1.6% at 6 months after cessation of CsA treatment (Figure 4). At 
that time, 1.4% LRH-1–specific CD8+ T cells could also be detected 
in the BM (data not shown). These in vivo–expanded LRH-1–specific 
CD8+ T cells displayed the CD45RA+CCR7–CD27– cytotoxic effector 
phenotype, indicative of an ongoing GVL reaction (data not shown). 
The number of circulating tetramer+ cells declined to 0.25% at 12 
months but persisted at a low frequency (0.05–0.10%) (Figure 4). 
Specific detection of LRH-1–specific CTLs by the tetramers was veri-
fied after in vitro stimulation of PBMC samples with peptide-pulsed 
donor EBV-LCLs. After 2 rounds of stimulation, tetramer+ CD8+ T 
cells markedly increased up to 6.8% for month 3, 13.9% for month 6, 
4.2% for month 12, and 2.0% for month 38 (Figure 4).
Correlation of the emergence of LRH-1–specific CTLs with clini-
cal outcome of DLI-2 revealed that the peak of tetramer+ cells was 
followed immediately by pancytopenia and a dramatic decrease 
in Bcr-Abl in the peripheral blood without an increase of GVHD 
(Figure 5, A and B). Thereafter, the patient remained in complete 
cytogenetic remission for more than 2 years despite readministra-
tion of CsA to treat chronic skin GVHD. However, 4 years after DLI-2, 
PCR for Bcr-Abl had become substantially positive (Figure 5B). 
The patient was given DLI-3 at a relatively low dose of 1 × 106 CD3+ 
cells/kg body weight in order to avoid severe GVHD. The patient 
did not develop GVHD, and her tumor transformed into CML in 
accelerated phase with almost all BM cells from recipient origin 
Table 2
Expression profile of candidate genes located between marker 
D17S1845 and D17S1876 on chromosome 17p13.2
	 	 Normalized	relative	gene	expressionC
GenesA	 Transcript	 Raji	 Monocytes	 Fibroblast
	 variantB
NYD-SP20 1 1.58 40.64 11.43
ASPA 1 4.21 26.63 12.95
TRPV3 1 8.14 4.79 7.54
TRPV1 1–4 2.51 2.16 1.11
CARKL 1 0.50 1.74 0.20
CTNS 1 0.72 0.37 0.21
TIP-1 1 1.54 3.43 6.66
MGC2963 1 2.68 3.46 0.70
P2X5 1–2 2.75 0.05 < 0.01
ITGAE 1 29.45 13.27 2.02
GSG2 1 4.10 19.09 4.13
HSA277841 1 3.17 9.55 6.73
CAMKK1 1–2 0.67 4.58 0.49
 3 9.48 38.05 3.51
P2X1 1 0.07 8.66 0.23
ATP2A3	 1–7 0.73 0.47 0.05
ZZEF1 1 7.84 85.63 2.50
MGC32124 1 0.91 0.79 0.82
ANKFY1 1 0.94 1.17 0.38
 2 4.79 1.91 0.90
UBE2G1 1–2 3.12 8.66 3.62
CTL recognitionD  + – –
AGenes retrieved from the NCBI database (Build 34) and the UCSC 
Genome Bioinformatics database (July 2003 freeze). Olfactory receptor 
genes are not listed. BRNA transcript variants detected with 1 set of PCR 
primers. CGene expression profile determined by real-time quantitative 
PCR using the SYBR green method. The housekeeping gene Pbgd was 
used for normalization. The expression in each cell type was calculated 
relative to the expression level measured in recipient EBV-LCLs using 
the ∆∆Ct method (39). DRecognition of cell type by CTL RP1.
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and with del(13) and t(4;11) as found during the first relapse. She 
was treated with imatinib mesylate (Glivec), and despite DLI-4 
(0.1 × 108 CD3+ cells/kg body weight) and DLI-5 (0.6 × 108 CD3+ 
cells/kg body weight), she entered myeloid blastic phase and died 
without GVHD. During this second relapse and concomitant 
treatment, LRH-1–specific CD8+ T cells were present but did not 
expand (Figure 5, A and B).
Selective expression of the P2X5 gene in leukemic and normal CD34+ 
progenitor cells, lymphoid cells, and lymphoid tissue. To more compre-
hensively define which cell types and tissues could be targeted by 
LRH-1–specific CTLs, we developed a real-time quantitative PCR 
that detects P2X5 transcripts encoding the LRH-1 epitope. The 
mean P2X5 RNA expression level compared with the reference 
cell line was 2.68 in EBV-LCLs, 0.28 in monocytes, and 0.10 in 
fibroblasts (Figure 6A). Based on our results that LRH-1–specific 
CTL recognizes EBV-LCLs but not monocytes and fibroblasts, 
we arbitrarily set the cutoff level at 0.4 to discriminate between 
LRH-1–positive and –negative cell types. CD34+CD38– and 
CD34+CD38+ cells isolated from myeloid leukemias, including 
CML in blast crisis and acute myeloid leukemia (AML), showed 
significant P2X5 RNA expression levels, as well as CD34+ pro-
genitor subsets isolated from normal BM and G-CSF–mobilized 
blood (Figure 6A). Interestingly, leukemic CD34+CD38– cells 
appear to have a significantly higher P2X5 RNA level compared 
with normal CD34+CD38– cells (P = 0.02; ANOVA; Figure 6A). 
CD34+CD38– cells obtained at first relapse from CML patient 
UPN389 had a relatively low P2X5 RNA expression of 0.61, 
whereas CD34+CD38+ cells had a higher expression level of 
2.67. A slightly lower P2X5 expression level of 1.31 was found in 
CD34+CD38+ cells obtained at second relapse (data not shown). 
We were unable to isolate enough CD34+CD38– cells (<5% of the 
total CD34+ population) from the second relapse sample. These 
data suggest that leukemic CD34+ progenitor subsets could be 
potentially targeted in vivo by LRH-1–specific CTLs.
Freshly isolated as well as cultured cells of the lymphoid lineage 
including B cells, EBV-LCLs, T cells, PHA–T cell blasts, and NK 
cells showed significant levels of P2X5 RNA expression (Figure 6B). 
In contrast, mature cells of the myeloid lineage including 
monocytes and DCs and nonhematopoietic cells including 
fibroblasts, keratinocytes, melanocytes, human umbilical vein 
endothelial cells (HUVECs), and proximal tubular epithelial cells 
(PTECs) had a very low level of or completely lacked P2X5 tran-
scription. Analysis of P2X5 expression in normal tissues showed 
high (>1.0) transcription levels in lymphoid tissues such as spleen, 
tonsils, thymus, and BM (Table 3). No significant (<0.4) P2X5 
expression could be detected in most adult normal tissues, except 
Figure 3
Identification of P2X5 as the gene encoding the HLA-B*0702–restricted epitope LRH-1. (A) IFN-γ production by CTL RP1 upon stimulation with 
EBV-LCL from the homozygous LRH-1–positive individual 1331-8234 and 293T-HLA-B*0702 cells transfected with full-length constructs of 
P2X5 transcript variants 1 and 2, and deletion constructs of P2X5 transcript variant 1 encoding the first 5 exons (Var 1 ∆5) either generated from 
EBV-LCL of the homozygous LRH-1–positive individual 1331–8234 or the homozygous LRH-1–negative stem cell donor. (B) Schematic repre-
sentation of the P2X5 gene on chromosome 17p13.2. The nucleotide and deduced aa sequences of exons 3 and 4 of both the LRH-1–positive 
and –negative allele present in recipient and donor, respectively, are shown. Disparity between the recipient and donor P2X5 protein sequence 
is due to a frameshift induced by a cytosine deletion polymorphism in the nucleotide sequence of exon 3 (5C versus 4C). This results in a dis-
parate aa sequence of 9 residues in the recipient direction (shaded box) and 35 residues in the donor direction (open box). The aa sequence of 
the antigenic epitope that is recognized by the HLA-B*0702–restricted CTL RP1 is underlined. (C) LRH-1 epitope reconstitution with synthetic 
peptides corresponding to the P2X5 exon 3 sequence of the recipient. Donor EBV-LCL was pulsed with various peptide concentrations and 
tested for recognition by CTL RP1. IFN-γ production was determined by ELISA.
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for low levels in neuronal and muscle tissue. Fetal brain showed 
a relatively high P2X5 expression level (2.80), whereas expression 
levels in the adult brain (0.43) and cerebellum (0.70) were much 
lower. Importantly, no P2X5 expression was detected in the GVHD 
target organs skin, liver, colon, and small intestine (Table 3). 
These data demonstrate that P2X5 is selectively expressed in leu-
kemic and normal CD34+ progenitor cells and hematopoietic cells 
of the lymphoid lineage.
Discussion
mHAgs play a pivotal role in inducing T cell responses mediating 
GVL reactivity after HLA-identical allogeneic SCT (4, 5). Molecu-
lar definition of mHAg peptides is crucial for the development of 
immunotherapeutic protocols to either selectively boost the GVL 
reaction or to inhibit GVHD. In this study, we have identified a 
novel hematopoietic cell–restricted mHAg, designated LRH-1, 
which is presented by HLA-B*0702 and encoded by the P2X5 puri-
nergic receptor gene. CTLs specific for LRH-1 (RP1 clone) were 
isolated from a CML patient that was successfully treated with 
high-dose DLI for relapse in accelerated phase after allogeneic 
SCT. Here, we show a direct association between in vivo expansion 
of LRH-1–specific CTLs and the disappearance of Bcr-Abl–positive 
CML tumor cells following DLI. These findings indicate a causative 
role for LRH-1 in GVL reactivity. Although the patient achieved a 
complete cytogenetic remission after high-dose DLI, low levels of 
Bcr-Abl transcripts remained detectable (Figure 5). Therefore, it 
remains to be investigated whether targeting of LRH-1 in patients 
with CML might be able to eradicate the most undifferentiated 
leukemic stem cells. GVHD was not increased by the emergence of 
LRH-1–specific CTLs despite interruption of CsA treatment. How-
ever, it is difficult to conclude that LRH-1–specific CTLs had no 
role in GVHD, since the patient required readministration of CsA 
for the treatment of chronic skin GVHD.
The level of expression of mHAgs may determine whether it is 
involved in GVL and/or GVHD (5). Previous studies by RNA dot 
blot analysis showed that P2X5 is selectively expressed in brain 
and lymphoid tissues (28). Here, we have used sensitive real-time 
quantitative PCR to determine relative expression levels of the 
P2X5 splice variant 1 encoding mHAg LRH-1. Our results con-
firm that P2X5 is highly expressed in various cell types of lym-
phoid origin and lymphoid tissues. Interestingly, we observed 
that the P2X5 gene is significantly expressed in leukemic CD34+ 
subpopulations from most CML as well as AML patients. We were 
unable, however, to demonstrate in vitro CTL RP1 recognition 
of CD34+ cells of the CML patient from whom the LRH-1–spe-
cific CTL was isolated (data not shown). This may be explained 
by the relatively low P2X5 expression level (0.61) in the leukemic 
CD34+CD38– progenitor subset of this CML patient, which rep-
resented approximately 50% of the total CD34+ population (data 
not shown). But, P2X5 expression in vivo could be higher, result-
Figure 4
Detection of LRH-1–specific CD8+ T cells 
in peripheral blood of CML patient UPN389 
after DLI. PBMCs collected 3, 6, 12, and 38 
months after DLI-2 were stained with LRH-1/
HLA-B7 tetramer, anti-CD8, anti-CD45, anti-
CD3, and 7-amino-actinomycin D (7AAD). 
Subsequently, cell populations were ana-
lyzed by flow cytometry. Cells were gated 
on CD45+CD3+7AAD– lymphocytes, and the 
percentages of tetramer-binding cells among 
CD8+ T cells are given. The remaining PBMCs 
were stimulated twice with LRH-1 peptide–
pulsed (10 µM) EBV-LCL of the donor and 
assayed on day 14 for LRH-1 tetramer-bind-
ing CD8+ T cells.
Figure 5
Longitudinal follow-up of LRH-1–specific CD8+ T cells in peripheral 
blood from CML patient UPN389 in relation to clinical outcome. (A) 
The percentage of LRH-1 tetramer-positive cells among CD8+ T 
cells (right y axis) are compared with the wbc count × 106 per ml 
peripheral blood (left y axis). (B) The percentages of LRH-1 tetra-
mer-positive cells among CD8+ T cells (right y axis) are compared 
with the relative units of Bcr-Abl in peripheral blood (left y axis). The 
lower level of detection of Bcr-Abl PCR is 4 × 10–6, depicted by the 
dotted line. Administration of DLIs 1–5 and stem cell (SC) boost 
are indicated by black and orange arrows, respectively. Treatment 
intervals with CsA and imatinib mesylate (Glivec) are shown by blue 
and yellow bars, respectively.
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ing in increased sensitivity to CTL recognition. The efficiency of 
killing of leukemic CD34+ progenitor cell subsets by LRH-1–spe-
cific CTLs is currently under investigation using sensitive in vitro 
progenitor cell cytotoxicity assays and could be studied in vivo in 
the NOD/SCID leukemia model (14, 29).
Importantly, P2X5 is not expressed in prominent GVHD tissues 
such as skin, liver, colon, and small intestine. Furthermore, mature 
cells of myeloid origin and various nonhematopoietic cell types 
were negative for P2X5. In nonlymphoid tissues, we detected only 
high P2X5 expression levels in fetal brain, whereas in adult tissues, 
we observed low expression in brain, cerebellum, and skeletal mus-
cle, which could not be explained by the presence of hematopoietic 
cells (Table 3). This low level of P2X5 expression could be caused 
by a small subset of cells present in these tissues (30, 31). But based 
on the fact that both brain and skeletal muscle are tissues that are 
not very likely to be infiltrated with lymphocytes without signifi-
cant inflammation (32), it seemed unlikely that LRH-1–specific 
CTLs damage these cells in vivo. This is supported by our finding 
that emergence of LRH-1–specific CTLs was not accompanied by 
significant toxicity to these organs.
Most previously described human mHAgs result from dispari-
ties in protein sequences between donor and recipient due to 
nonsynonymous SNPs in their encoding genes. The resulting 
aa substitutions may affect either peptide processing by the 
proteasome (10), transporter associated with antigen process-
ing translocation of the peptide into the ER (23), binding of the 
peptide to MHC (8), or recognition of the MHC-peptide complex 
by mHAg-specific T cells (20, 22, 33). In the case of an mHAg 
encoded by the UGT2B17 gene, disparity resulted from differen-
tial protein expression due to a homozygous gene deletion in the 
donor, although the genetic basis for this gene deletion remains 
to be elucidated (25). Here, we demonstrate for 
the first time to our knowledge that mHAgs can 
arise from frameshift polymorphisms that are dis-
parate between recipients and their HLA-identical 
transplant donors.
P2X5 is a member of the P2X purinergic recep-
tor family consisting of at least 7 proteins, P2X1 to 
P2X7, which are capable of forming ATP-gated cat-
ion channels by homo- or heteromultimerization 
(34). Transcription of the human P2X5 gene results 
in expression of 2 major isoforms as a result of dif-
ferential splicing (28). Splice variant 1 encodes 
a long isoform consisting of 422 aas, whereas 
translation of splice variant 2 results in a shorter 
isoform lacking exon 3 (397 aas). Our results indi-
cate that a donor-specific, homozygous frameshift 
polymorphism in exon 3 of splice variant 1 leads 
to the formation of a truncated aberrant version 
of the long P2X5 isoform. Hence, donor-derived T 
lymphocytes are not tolerant of the wild-type exon 
3 of the recipient. The high genotype frequency 
(i.e., 46%; unpublished observations) of healthy 
individuals that are homozygous for the cytosine 
deletion in exon 3 indicates that deficiency for the 
long P2X5 isoform is common without any signifi-
cant phenotypic characteristics. The short P2X5 
isoform as well as redundancy among P2X family 
members may compensate for the deficiency of the 
long P2X5 isoform.
Hematopoietic cell–restricted mHAgs are suitable targets for 
the application of immunotherapy to prevent or to treat recur-
rences of hematopoietic malignancies after allogeneic SCT. Based 
on its hematopoietic-specific expression, the P2X5-encoded 
mHAg LRH-1 could be an attractive candidate. P2X5 is highly 
expressed in a broad range of lymphoid malignancies including 
T and B cell acute lymphoblastic leukemia, chronic lymphocytic 
leukemia, various types of B cell lymphoma, and multiple myelo-
ma (unpublished observations). Furthermore, CD34+CD38– and 
CD34+CD38+ myeloid leukemic progenitor cells were found to 
have enriched levels of P2X5 transcripts compared with mature 
nonleukemic monocytes (P < 0.05; ANOVA; Figure 6A), suggest-
ing that LRH-1–specific CTLs may preferentially target immature 
myeloid leukemia cells. Therefore, vaccination with the LRH-1 
peptide would be an attractive approach for induction of GVL 
reactivity. Recently we developed a genotyping assay for the LRH-1 
mHAg, and of the 45 HLA-B7–positive SCT donors and recipi-
ents analyzed so far, 6 patients (∼13%) positive for LRH-1 mHAg 
received a transplant from an LRH-1–negative donor (unpub-
lished observations). These patients would be eligible for LRH-1 
peptide–based vaccination. Studies are underway to determine 
whether LRH-1–specific CD8+ T cells can be detected or induced 
ex vivo in these LRH-1 disparate transplant recipients.
In conclusion, we describe a novel hematopoietic cell–restricted 
mHAg, designated LRH-1, that can function as a GVL-specific anti-
gen for hematological malignancies. The significance of mHAg 
LRH-1 for cellular immunotherapy of relapsed leukemia is demon-
strated by the direct correlation between expansion of LRH-1–spe-
cific CTLs and disappearance of CML, and the expression of its 
encoding gene in leukemic CD34+ progenitor cells. In addition, we 
describe a novel mechanism responsible for antigenicity of mHAg 
Figure 6
P2X5 gene expression is restricted to leukemic and normal CD34+ progenitor cells as 
well as lymphoid cells. (A) P2X5 expression determined by real-time quantitative PCR 
in CD34+ subpopulations isolated from leukemia patients (CML blast crises, n = 4 and 
acute myeloid leukemia, n = 10) and healthy stem cell donors (normal BM, n = 4 and 
G-CSF–mobilized peripheral blood, n = 5). Leukemic CD34+ subsets isolated from 
CML patient UPN389 at first relapse are indicated by the arrows. (B) P2X5 expression 
determined by real-time quantitative RT-PCR in freshly isolated cells or primary cell 
cultures of hematopoietic and nonhematopoietic origin. Expression is shown relative to 
the P2X5 expression measured in the reference cell line JVM-2, which is susceptible 
to lysis by the LRH-1–specific CTL RP1. The housekeeping Pbgd gene was used for 
normalization. Cell types with P2X5 expression less than 0.4 were not recognized by 
CTL RP1, indicating that these cell types can be considered as LRH-1 negative. This 
arbitrary threshold is indicated with a dashed line. The mean expression level for each 
cell population is shown by the thick line.
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LRH-1. Our data demonstrate for the first time to our knowledge 
that differential protein expression as a consequence of a homo-
zygous frameshift polymorphism is the basis for mHAg disparity. 
This novel mechanism may apply to other mHAgs involved in allo-
responses after HLA-identical allogeneic SCT.
Methods
Cell isolation and culture. CD8+ CTL clone RP1 was isolated from PBMCs 
obtained 3 months after DLI-2 by weekly stimulation with CML cells 
obtained at hematological relapse in Iscove’s modified Dulbecco’s medium 
(IMDM) (Invitrogen Corp.) supplemented with 10% human serum (HS) 
(PAA Laboratories).	Relapse CML cells that were used as stimulator cells 
contained 5% CD34+ blasts, 3% CD19+ B cells, 29% CD3+ T cells, and 60% 
CD13+CD33+ myeloid cells. Myeloid cells were completely of recipient ori-
gin, and lymphocytes were mixed chimeric.	After initial stimulation, CTL 
RP1 (0.5 × 106) was cultured in IMDM/10% HS containing irradiated (80 Gy) 
recipient EBV-LCLs (0.5 × 106), irradiated (60 Gy) allogeneic PBMCs (0.5 × 106) 
from 2 donors, 100 IU/ml IL-2 (Eurocetus), and 1 µg/ml PHA-M (Boer-
hinger) in a total volume of 2 ml. The HLA-B7–alloreactive CTL KOR18 
was kindly provided by E. Goulmy (Leiden University Medical Center). CTL 
KOR18 (2 × 106) was cultured in IMDM/10% HS containing irradiated 
HLA-B7–positive EBV-LCLs (5 × 106), irradiated allogeneic PBMCs (5 × 106) 
from 2 donors, 100 IU/ml IL-2, and 1 µg/ml PHA-M in a total volume of 
15 ml. CTL cultures were used in cytotoxicity and stimulation assays either 
7 days after stimulation or 1 day after thawing a frozen aliquot. All cell 
lines and primary cells were cultured in IMDM/10% FCS. EBV-LCLs from 
the CEPH families were provided by P. Martin (Fred Hutchinson Cancer 
Research Center, Seattle, Washington, USA) or purchased from the Coriell 
Institute for Medical Research. B cells, T cells, and monocytes were isolated 
from PBMCs using anti-CD19, anti-CD3, and anti-CD14 immunomag-
netic beads (Miltenyi Biotec), respectively. B cell blasts were generated by 
culturing CD19+ B cells in IMDM/10% HS with 1 µg/ml CD40L (gift from 
Immunex Corp.) and 100 U/ml IL-4 (Schering-Plough) for 5 days. T cell 
blasts were generated by stimulating CD3+ T cells in IMDM/10% HS with 
20 µg/ml PHA-M for 3 days. Thereafter, PHA-activated T cells were washed 
and further cultured with 100 IU/ml IL-2 for 2 additional days. Immature 
DCs were generated by culturing CD14+ monocytes in IMDM/5% HS with 
800 U/ml GM-CSF (Schering-Plough) and 500 U/ml IL-4 for 6 days. Imma-
ture DCs were maturated by culturing for 3 additional days in IMDM/5% 
HS with 800 U/ml GM-CSF, 500 U/ml IL-4, 20 ng/ml TNF-α (Endogen), 
and 10 µg/ml Prostin E2 (Pfizer). Fibroblasts were isolated from BM aspi-
rates of healthy stem cell donors. BM was resuspended in 20 ml IMDM/20% 
FCS and incubated overnight in 75-cm2 tissue culture flasks. The nonad-
herent fraction was removed, and fibroblasts were further cultured in 
IMDM/20% FCS to passage 3 before analysis.
Chromium release assay. Chromium release assays were performed to 
assess cytolytic activity of CTLs as described previously (12). Fibroblasts 
were pretreated with 10 ng/ml TNF-α and 100 U/ml IFN-γ (Boehringer)	
for 2 days before 51Cr labeling. The following Abs were used for inhibition 
of CTL reactivity: SPV-T3b (anti-CD3), W6/32 (anti–HLA class I), B1.23.2 
(anti–HLA-B/C), and SPVL-3 (anti–HLA-DQ).
Retroviral transduction of HLA-B*0702 in cell lines and CTL stimulation assay. 
HLA-B*0702 cDNA (provided by E. Goulmy) was subcloned in the LZRS-
IRES-EGFP vector. The resulting LZRS-HLA-B*0702-IRES-EGFP vector was 
used to generate a stable producer cell line. Retroviral transduction was per-
formed using non–tissue culture–treated 35-mm2 dishes (BD) coated with 
10 µg/ml RetroNectin (Takara Bio Inc.). Target cells (106) were resuspended 
in 2 ml virus supernatant and transferred to RetroNectin-coated dishes. After 
24 hours of incubation, cells were collected and incubated with fresh virus 
supernatant. Finally, transduced cells were cultured for 5 additional days 
before use in CTL stimulation assays as described previously (13). Release of 
IFN-γ was determined by ELISA (Endogen; Pierce Biotechnology Inc.).
Genetic linkage analysis. Mapping of the LRH-1 locus was accomplished 
in a subset of CEPH reference families. Genotypes were retrieved from 
the CEPH database, version 9.0 (http://www.cephb.fr/cephdb/; refs. 35, 
36). Two-point linkage was performed using the MLINK subroutine of 
the FASTLINK (version 4.0) program (http://www.cs.rice.edu/∼schaffer/
fastlink.html) as reported previously (11, 36, 37). An autosomal dominant, 
single gene model was assumed for the LRH-1 trait. The population fre-
quency of the encoding allele was estimated at 0.5 and the penetrance of 
the LRH-1 phenotype was set at 0.9. Population allele frequencies for the 
genetic markers were used when present in the CEPH database; otherwise 
equal allele frequencies were assumed. Resulting lod scores were examined 
for regions of highly significant linkage, and the identification of the LRH-1 
locus was interpreted from the Marshfield genetic map (38).
Real-time PCR analysis of candidate genes. Total RNA was isolated by the 
TRIzol method (Invitrogen Corp.) and treated with DNase. First-strand 
cDNA was prepared using oligo-dT primer and Powerscript RT (BD Bio-
sciences — Clontech). Gene-specific primer sets were designed at the 3′ 
end of each candidate gene. One microliter of cDNA was amplified in a 
50-µl reaction mixture containing 1.25 U AmpliTaq Gold (Applied Bio-
systems), 300 nM of each primer, 250 µM of each dNTP, 5 mM MgCl2, 
and 1× SYBR green PCR buffer (Applied Biosystems). The porphobilinogen 
deaminase (Pbgd) gene was used to normalize expression of each candi-
date gene. The following primers and TaqMan probe were used for Pbgd 
real-time PCR: Pbgd-F 5′-GGCAATGCGGCTGCAA-3′, Pbgd-R 5′-GGG-
TACCCACGCGAATCAC-3′, and Pbgd-probe 5′-(VIC)-CTCATCTTT-
Table 3
P2X5 and CD45 gene expression in normal tissues
Normal		 P2X5		 CD45		 Ratio		
tissue	 expression	 expression	 (P2X5/CD45)
Adrenal gland 0.03 0.21 0.1
Bone marrow 1.58 5.25 0.3
Brain 0.43 0.02 21.5
Cerebellum 0.70 0.07 10.0
Colon 0.12 0.10 1.2
Fetal brain 2.80 0.06 46.7
Fetal liver 0.14 0.14 1.0
Heart 0.49 0.28 1.8
Kidney 0.02 0.06 0.3
Liver 0.01 0.15 < 0.1
Lung 0.48 2.51 0.2
Placenta 0.04 0.99 < 0.1
Prostate 0.19 1.70 0.1
Salivary gland 0.37 0.13 2.8
Skeletal muscle 0.56 0.01 56.0
Skin 0.01 0.80 < 0.1
Small intestine 0.16 0.46 0.3
Spinal cord 0.35 0.67 0.5
Spleen 21.86 11.06 2.0
Stomach 0.34 1.47 0.2
Testis 0.11 0.09 1.2
Thymus 6.43 18.04 0.4
Thyroid gland 0.33 0.56 0.6
Tonsils 21.00 18.58 1.1
Trachea 0.76 0.78 1.0
Normalized mRNA expression of P2X5 transcript variant 1 and CD45 
was determined by real-time quantitative PCR and expressed relative to 
the expression level in the JVM-2 cell line.
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GGGCTGTTTTCTTCCGCC-(TAMRA)-3′. Pbgd-PCR was performed as 
described above using 300 nM TaqMan probe. PCR amplification was 
performed using an ABI Prism 7700 (Applied Biosystems) with the follow-
ing PCR conditions: enzyme activation for 10 minutes at 95°C, followed 
by 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. The cycle 
threshold (Ct) was determined by software analysis (Sequence Detection 
System, version 1.9.1; Applied Biosystems). The expression of candidate 
genes was calculated using EBV-LCLs of the recipient as calibrator with 
the following formula: [2–(∆∆Ct)] × 100 (39).
Construction of full-length and truncated P2X5 plasmids. Constructs con-
taining the full-length or a truncated form of the P2X5 transcript 
variants were generated by PCR. cDNA was prepared from a homozy-
gous LRH-1–positive and LRH-1–negative EBV-LCLs and amplified 
using specific primers. The following primers were used: P2X5-FLF 
5′-CATGGGGCAGGCGGG-3′ and P2X5-FLR 5′-AACGTAAGCAGAG-
GCAATTCACGT-3′. A truncated form containing exons 1–5 of P2X5 
transcript variant 1 was generated with the P2X5-FLF forward primer 
and reverse primer P2X5-TRR 5′-GGGGAAACGGATGTGGTTCT-3′. 
PCR products were purified using the QIAGEN gel extraction kit and 
cloned into vector pCR3 (Invitrogen Corp.)	using the unidirectional TA 
cloning kit (Invitrogen Corp.). Plasmids (400 ng) were used for trans-
fection into 3.5 × 104 293T-HLA-B*0702 cells plated in poly-d-lysine–
coated 96-well flat-bottom wells (BD) using Lipofectamine (Invitrogen 
Corp.). Transfected cells were cultured for 2 additional days and used in 
CTL stimulation assays.
Epitope prediction and reconstitution assay. HLA-B7–binding peptides were 
predicted using BIMAS software (http://bimas.dcrt.nih.gov/molbio/hla_
bind/; ref. 40). Peptides were synthesized by solid-phase strategies on an 
automated multiple peptide synthesizer (AMS 422; ABIMED). Peptides 
were purified by reverse-phase HPLC and lyophilized. Finally, peptides 
were dissolved in DMSO, diluted in IMDM to a concentration of 1 mM, 
and stored at –20°C before use. In peptide recognition assays, target cells 
were preincubated with various concentrations of peptide for 30 minutes 
in a volume of 100 µl prior to the addition of CTLs.
Tetramer staining. PE-labeled LRH-1/HLA-B7 tetramers using peptide 
TPNQRQNVC were produced as described previously (41). LRH-1 tet-
ramers were validated by staining against CTL RP1. For staining, PBMC 
or CTL cell lines were incubated with 20 µg/ml LRH-1 tetramer for 30 
minutes at room temperature. After washing with PBS/0.5% BSA, cells 
were labeled with the appropriate concentration anti-CD8 (LT8-FITC; 
ProImmune), anti-CD3 (UCHT1-Cy7; Beckman Coulter), anti-CD45 
(J33-ECD; Beckman Coulter), and 1 µg/ml 7-amino-actinomycin D 
(7AAD) at room temperature for 15 minutes. After washing, cells were 
resuspended in PBS/0.5% BSA and analyzed using the Coulter FC500 
flow cytometer (Beckman Coulter).
Bcr-Abl PCR analysis. Bcr-Abl PCR analysis was performed on an ABI 
Prism 7700 system (Applied Biosystems) as described previously (42). In 
brief, total RNA from cells was extracted using TRIzol (Invitrogen Corp.). 
Reverse transcription was performed on 1 µg of total RNA using random 
hexamers and Mo-MuLV RT (Invitrogen Corp). Expression of the Pbgd 
gene	was used to normalize Bcr-Abl expression. This normalized Bcr-Abl 
expression in patient samples was related to a standard curve obtained 
from K562 cells diluted into normal BM cells.
Real-time quantitative PCR analysis of P2X5 gene. PBMCs were isolated 
from normal donors using Ficoll-Paque (Amersham Biosciences) 
and used for isolation of different cell subsets. PBMCs were labeled 
with the appropriate concentration of FITC-, PE-, and/or Cy5-conju-
gated Abs. Labeled cells were sorted into CD19+ B cells, CD3+ T cells, 
CD3–CD16/56+ NK cells, and CD14+ monocytes using the Coulter 
EPICS Elite flow cytometer (Beckman Coulter). Normal and leukemic 
CD34+CD38– and CD34+CD38+ cells were sorted from cell suspensions 
after labeling with CD34-FITC and CD38-PE Abs (BD). Immature DCs, 
mature DCs, and fibroblasts were cultured as described above. Kerati-
nocytes were provided by S. Ebeling (University Medical Center Utre-
cht, Utrecht, The Netherlands). PTECs, HUVECs, and melanocytes were 
provided by E. Spierings (Leiden University Medical Center). Total RNA 
from each of these cell types was isolated using the Zymo RNA isola-
tion kit II (Zymo Research Corp.). RNA of normal tissues was obtained 
from the RNA Master Panel II (BD Biosciences — Clontech). First-strand 
cDNA was prepared from total RNA using oligo-dT, random hexamers, 
and Mo-MuLV RT (Invitrogen Corp.). In parallel to P2X5 expression, 
we used CD45 expression to detect the presence of hematopoietic cells 
in normal tissues. The Pbgd housekeeping gene was used to normalize 
P2X5 and CD45 expression. One microliter of cDNA was amplified in 
a 50-µl reaction mixture containing 1.25 U AmpliTaq Gold (Applied 
Biosystems), 300 nM gene-specific forward and reverse primer, 150–300 
mM gene-specific TaqMan probe (150 nM for P2X5, 200 nM for CD45, 
and 300 nM for Pbgd), 250 µM of each dNTP, 5 mM MgCl2, and 1× 
TaqMan PCR buffer (Applied Biosystems). The following gene-specific 
primers and TaqMan probes were used: P2X5: P2X5-F 5′-TCCTGGCG-
TACCTGGTCGT-3′, P2X5-R 5′-CTTCATTCTCAGCACAGACGTTC-3′, 
and P2X5-probe 5′-(TET)-TGGGTGTTCCTGATAAAGAAGGGTTAC-
CA-(TAMRA)-3′; and CD45: CD45-F 5′-TTAGAAATGAGTCGCATA-
AGAATTGC-3′, CD45-R 5′-CTCCAGGATAGTCTCCATTGTGAAA-3′, 
and CD45-probe 5′-(TET)-ATTTCCGTGTAAAAGATC-(TAMRA)-3′. 
PCR conditions were as follows: enzyme activation for 10 minutes at 
95°C, followed by 45 cycles of 95°C for 15 seconds and 60°C for 1 min-
ute. P2X5 and CD45 mRNA expression was quantified by determining 
calibration functions using JVM-2 as reference cell line. The level of 
P2X5 and CD45 expression of test samples was calculated relative to the 
P2X5 and CD45 expression in the JVM-2 cell line. P2X5 mRNA expres-
sion levels of different cell types were compared using ANOVA and Dun-
can post-hoc comparison. P < 0.05 was considered significant.
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